Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (January 2024)
26 slides from Revelation Biosciences's investor presentation, Jan 30, 2024
Slide 1: Developing innovative therapeutics to address unmet needs
Developing innovative therapeutics to address unmet needs Corporate Presentation / January 2024 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w
Slide 3: Therapeutic Development Pipeline
Program Name (Indication) 2023 2024 2025 GEM-SSI (Gemini for the prevention of SSI) GEM-AKI (Gemini for the prevention of AKI) GEM-CKD (Gemini for the prevention of CKD) Therapeutic Development Pipeline Revelation has a pipeline of potential high-value products based on Gemini Gemini is Revelation’s
Slide 4: PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications
PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications 1. Zwirner, N. and Ziblat, A. 2017 doi: 10.3389/fimmu.2017.00025 2. Ismaeli, J. et. al. 2022 doi: 10.4049/jimmunol.168.2.926 3. Hernandez, A. et. al. 2019 DOI: 10.1097/CCM.0000000000003967 4. Revelation Data Gemini administrati
Slide 5: GEM-HAI Program: Gemini for the Prevention of Hospital Acquired Infection
GEM-HAI Program Gemini for the Prevention of Hospital Acquired Infection
Slide 6: GEM-HAI Program Highlights
GEM-HAI Program Highlights Scientific Rationale 1. 2015 HAI and Antibiotic Use Prevalence Survey, CDC.gov Gemini preconditions the innate immune system through a process of trained immunity, comprising redirection and attenuation of the innate immune system’s response to external stress (infection,
Slide 7: Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection
Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection Hernandez, et. al. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. DOI: 10.1097/CCM.0000000000003967 Study Design: Mice were pre-treated (24 and 48 hours) with vehicle
Slide 8: Pretreatment with PHADs Impart Protection from Gram Positive Bacterial Infection
Study Design: Mice were pre-treated (24 and 48 hours) with vehicle, MPLA (1 mg/kg), or PHADs (1 mg/kg) prior to infection with S. aureus. All given IV. Bacterial counts assessed 3 days post infection. n = 7 to 10 animals per group. Pre-treatment with MPLA and PHAD(s) demonstrated improved pathogen c
Slide 9: Healthy Animal Study: Gemini Administration Induces White Blood Cell Mobilization
Study Design: Dogs received a single dose of vehicle Gemini and blood samples were collected at various time-points up to 24 hours post dose for analysis (n=3–10 per group) Healthy Animal Study: Gemini Administration Induces White Blood Cell Mobilization Gemini administration results in white blood
Slide 10: Healthy Animal Study: Gemini Administration Induces Key Cytokines
Healthy Animal Study: Gemini Administration Induces Key Cytokines Gemini administration resulted in a dose dependent increase in cytokines following a single dose IL-10 is characterized as an anti-inflammatory cytokine leading to the ultimate resolution of inflammation. NGAL (data not shown) sequest
Slide 11: Phase 1 Clinical Study
Phase 1 Clinical Study1 8 subjects per cohort randomized 1:4 placebo vs drug Study start anticipated in Q1 2024 Title: A Phase 1, Randomized, Placebo Controlled, Single Blind, Single-Ascending Dose in Healthy Volunteers Part 1 Single ascending doses of Gemini followed for 7 days, 5 cohorts total Rea
Slide 12: Total US Addressable Market for Post-surgical Infection is over 6.3M Annual Procedures
Total US Addressable Market for Post-surgical Infection is over 6.3M Annual Procedures Surgeries in Hospital-Based Ambulatory Surgery and Hospital Inpatient Settings, 2014 Claudia A. Steiner, M.D., M.P.H., Zeynal Karaca, Ph.D., Brian J. Moore, Ph.D., Melina C. Imshaug, M.P.H., and Gary Pickens, Ph.D
Slide 13: The Impact of Surgical-Site Infections (SSI)
The Impact of Surgical-Site Infections (SSI) DOI:10.1001/jamasurg DOI:10.1086/676022 DOI: 10.1016/j.jamcollsurg.2016.10.029 ~€11bn represents the midpoint of the range discussed in WHO Global guidelines on the prevention of surgical site infection. Nov 2016 DOI: 10.1086/501572 Up to 30% Estimated SS
Slide 14: GEM-AKI and GEM-CKD Programs
GEM-AKI and GEM-CKD Programs Gemini For the Prevention of Acute Kidney Injury and Chronic Kidney Disease
Slide 15: GEM-AKI Program Highlights
Gemini preconditions the innate immune system through a process of trained immunity, comprising redirection and attenuation of the innate immune system’s response to external stress (infection, trauma, etc.) Allows for rapid response to external stress Downregulates the pro-inflammatory response, re
Slide 16: PHAD Pretreatment Reduces AKI in a Unilateral Ischemia/Reperfusion Model
PHAD Pretreatment Reduces AKI in a Unilateral Ischemia/Reperfusion Model 1 1. Hernandez A, Patil N, et. al. Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology 2023 324:5, F472-F482 Mice pretreated with
Slide 17: PHAD Pretreatment Reduces AKI in a Bilateral Ischemia/Reperfusion Model
PHAD Pretreatment Reduces AKI in a Bilateral Ischemia/Reperfusion Model1 1. Hernandez A, Patil N, et. al. Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology 2023 324:5, F472-F482 Mice were pretreated wi
Slide 18: Gemini Treatment Reduces Fibrosis in Acute and Chronic Kidney Model
Gemini Treatment Reduces Fibrosis in Acute and Chronic Kidney Model (UUO in Rats) Composite data represents the average of 3 anatomically distinct depths (10 images / depth / rat / group = ~60-65% of renal cortical area) Renal cortical fibrosis, expressed as Collagen Volume Fraction (CVF; via quanti
Slide 19: Gemini Antifibrotic Effects Likely Mediated by Validated Target Cytokines
Gemini Antifibrotic Effects Likely Mediated by Validated Target Cytokines TGF-β is pro-fibrotic and is directly linked to the propagation of fibrosis1,2,3,4 IL-10 is a key driver for the reduction and resolution of inflammation NGAL is an important defense for preventing excessive oxidative damage r
Slide 20: Phase 1 Clinical Study
Phase 1 Clinical Study1 8 subjects per cohort randomized 1:4 placebo vs drug Study start anticipated in Q1 2024 Title: A Phase 1, Randomized, Placebo Controlled, Single Blind, Single-Ascending Dose in Healthy Volunteers Part 1 Single ascending doses of Gemini followed for 7 days, 5 cohorts total Rea
Slide 21: Total US Addressable Market for AKI and CKD is over 42M Annual Potential Patients
Total US Addressable Market for AKI and CKD is over 42M Annual Potential Patients Our initial strategy will be to seek approval for prevention of AKI following surgery Initial clinical studies will enroll patients undergoing cardiac surgery Conservatively, if we treat 20% of the cardiac surgery AKI
Slide 22: AKI Epidemiology
AKI Epidemiology In the US, 1% of all hospital admissions have AKI on admission1 During hospitalization, the approximate incidence rate of acute kidney injury is 2 to 5% and it develops in up to 67% of patients admitted in the intensive care unit1 AKI is an important contributor to increased hospita
Slide 23: AKI as a Result of Cardiac Surgery
AKI as a Result of Cardiac Surgery DOI: 10.2147/IJNRD.S167477 DOI: 10.1097/ACO.0000000000000422 DOI: 10.214470/1678-9741-2018-0084 Up to 31% Of patients undergoing cardiac surgery with no prior CKD develop post operative AKI3 50% Death rate of patients that develop post operative AKI2 $42.6k Average
Slide 24: Financial Overview
> REVELATION Financial Overview ~ BAOESI@IIEINIGIESS
Slide 25: Management and 5% holdings; Cap Table
Management and 5% holdings Percent Total management 1.7% Sabby Volatility Warrant Master Fund, Ltd. 6.4% Cap Table Shares Common Stock Outstanding 209,911 Class C common stock warrants w/$5.36 exercise 16,239 Public Warrants w/$402.50 exercise (REVBW) 10,012 Warrants w/$24.20 weighted avg exercise1
Slide 26: Thank you!
For more information please visit www.revbiosciences.com Thank you!
Revelation Biosciences — Investor Presentation (January 2024) on 6ix